AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. (November 2015)

• Record Type: Journal Article
• Authors: Remon, Jordi; Planchard, David
• Is Part Of: Future oncology. Volume 11:Number 22(2015)
• Page Start: 3069
• Page End: 3081
• Publication Date: 2015-11
• Subjects: AURA -- AZD9291 -- EGFR mutant -- non-small-cell lung cancer; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.250
• Languages: English
• ISSNs: 1479-6694

Abstract

Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR -activating mutation develop acquired resistance after a median of 9–11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. T790M mutation is the cause of this resistance in approximately 60% of cases. AZD9291 is an oral, irreversible, mutant-selective EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to have potency against EGFR mutations, including T790M mutation, while sparing wild-type EGFR . A Phase I trial of AZD9291 in EGFR -mutant NSCLC patients, demonstrated high activity, essentially among T790M-mutant tumors, with a manageable tolerability profile. Ongoing Phase III trials are evaluating AZD9291 in EGFR -mutant patients as first-line treatment compared with erlotinib and gefitinib; and as second-line treatment compared with chemotherapy after progression on EGFR TKI in T790M-mutant tumors. Better identification of T790M-mutant tumors post EGFR TKI relapse and mechanisms of resistance to AZD9291 are the future challenges. This article reviews the emerging data regarding AZD9291 in the treatment of patients with advanced NSCLC.